Senseonics said yesterday it inked a collaborative deal with Diasend to use its diasend Clinic and diasend Personal solutions to analyze data from Senseonics Eversense continuous glucose monitoring system.
Under the agreement, patients and clinicians will be able to use Diasend’s programs to review past Eversense CGM data, as well as insulin pump and activity tracker data, the companies said.
“We believe that turning data from CGM and or pump devices into actionable data is extremely important to users. Our aim with the Eversense CGM system is to help people with diabetes spend less time managing their devices and more time managing their diabetes. In our clinical trials we have observed the Eversense sensor to last up to 90 days, the smart transmitter is removable and can provide on-body vibe alerts and the mobile application provides real-time glucose readings and alerts. We have also incorporated easy to understand pre-formatted glucose reports so users can see past data and trends directly on the application. Senseonics is extremely pleased to be working with a partner as valuable as Diasend, a company that is already well-known and trusted by the diabetes community, to allow users to have access to additional historical data and a more comprehensive data management solution,” Senseonics CEO Dr. Tim Goodnow said in prepared remarks.
The Eversense monitor uses a subcutaneous sensor and an external, removable smart transmitter linked to a mobile app that delivers real-time glucose levels and can be set to transmit alerts and alarms, the company said.
“Our solution is currently used in over 2,500 clinics, by more than 130,000 patients every month across the world. Clinics have come to rely on our unified reports for all different patient devices on the market today. By providing the Eversense CGM’s 90-day data along with other devices in familiar looking reports, we will contribute to a consistent analysis that is optimal for both healthcare professionals in the clinic environment and for a person with diabetes in a home setting via the Diasend Mobile app or web application,” Diasend CEO Anders Sonesson said in a press release.
In late January, Senseonics said it launched the Precise II trial of its Eversense CGM for individuals suffering from diabetes.
The blinded, non-randomized study is looking to examine the accuracy, safety and efficacy of the Eversense system up to 90-days after implant, the Germantown, Md.-based company said.
A week prior, Senseonics registered for an initial public offering worth up to $51.8 million as it gears up to get its Eversense on the diabetes market.
